Payment overview · 2025
General Payments
$1,311.01
66 reported records · 19 companies
Healthcare provider profile · identity verified
Cassandra Patterson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · COLUMBIA, SC · NPI 1851500821
Verified facts
What the public records show
CMS Open Payments records show Cassandra Patterson, MD received $1,311.01 in general payments during 2025 across 66 reported records.
ABBVIE INC. accounted for 14.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Mounjaro, Nurtec Odt, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $186.15 | 14.2% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $150.86 | 11.5% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $149.57 | 11.4% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $126.59 | 9.7% | 7 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $121.85 | 9.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $117.51 | 9.0% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $56.11 | 4.3% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $49.66 | 3.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $49.18 | 3.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $48.85 | 3.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $48.56 | 3.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.03 | 3.3% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $37.09 | 2.8% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $28.73 | 2.2% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $26.16 | 2.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.22 | 1.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.19 | 1.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.95 | 1.4% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $16.75 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,212.01 | 65 |
| Education | $99.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $129.85 | 9 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $126.59 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $119.91 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $76.12 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $75.87 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.84 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $49.66 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $49.18 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.56 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $45.59 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $37.39 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $37.39 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $37.39 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $37.09 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.95 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.95 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.60 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.15 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $28.73 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $26.70 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $26.16 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 27 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 536 | 148 |
| Atorvastatin Calcium | Atorvastatin Calcium | 384 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 314 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 233 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 197 | 55 |
| Gabapentin | Gabapentin | 180 | 54 |
| Losartan Potassium | Losartan Potassium | 167 | 52 |
| Omeprazole | Omeprazole | 167 | 50 |
| Furosemide | Furosemide | 150 | 49 |
| Pregabalin | Pregabalin | 148 | 44 |
| Lisinopril | Lisinopril | 142 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 135 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 129 | 41 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 127 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 127 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 29 |
| Famotidine | Famotidine | 114 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 114 | 31 |
| Montelukast Sodium | Montelukast Sodium | 108 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 102 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 33 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 98 | 28 |
| Clonazepam | Clonazepam | 88 | 13 |
| Meloxicam | Meloxicam | 80 | 34 |
| Januvia | Sitagliptin Phosphate | 72 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 15 |
| Alendronate Sodium | Alendronate Sodium | 64 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 20 |
| Metformin Hcl | Metformin Hcl | 61 | 16 |
| Bupropion Xl | Bupropion Hcl | 60 | 15 |
| Carvedilol | Carvedilol | 54 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 20 |
| Sertraline Hcl | Sertraline Hcl | 54 | 15 |
| Tramadol Hcl | Tramadol Hcl | 54 | 26 |
| Simvastatin | Simvastatin | 53 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 23 |
| Ondansetron Odt | Ondansetron | 47 | 30 |
| Metformin Hcl Er | Metformin Hcl | 46 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 12 |
| Ozempic | Semaglutide | 45 | suppressed |
| Myrbetriq | Mirabegron | 44 | 11 |
| Cefdinir | Cefdinir | 43 | 41 |
| Topiramate | Topiramate | 40 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 39 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | suppressed |
| Eliquis | Apixaban | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 36 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | 13 |
| Farxiga | Dapagliflozin Propanediol | 35 | 11 |
| Prednisone | Prednisone | 35 | 25 |
| Clonidine Hcl | Clonidine Hcl | 34 | 11 |
| Trazodone Hcl | Trazodone Hcl | 34 | 13 |
| Allopurinol | Allopurinol | 33 | 11 |
| Potassium Chloride | Potassium Chloride | 33 | suppressed |
| Irbesartan | Irbesartan | 32 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 13 |
| Jardiance | Empagliflozin | 27 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 24 |
| Fluconazole | Fluconazole | 26 | 20 |
| Valacyclovir | Valacyclovir Hcl | 25 | 13 |
| Lorazepam | Lorazepam | 24 | suppressed |
| Nystatin | Nystatin | 24 | 17 |
| Linzess | Linaclotide | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | 12 |
| Azithromycin | Azithromycin | 21 | 15 |
| Trulicity | Dulaglutide | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | 11 |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | 11 |
| Diazepam | Diazepam | 17 | suppressed |
| Fluocinonide | Fluocinonide | 17 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,311.01 · 66 records | ABBVIE INC. | ABRYSVO, ACCRUFER, AIRSUPRA, BREZTRI, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, EVENITY, FARXIGA, GARDASIL 9, GEMTESA, JARDIANCE, Korlym, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, Rybelsus, SAPIEN 3 Ultra RESILIA, SPRAVATO, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error